Triplet Therapeutics, Inc.

Triplet Therapeutics, Inc. is a biotechnology company focused on developing transformative therapies for genetically-driven diseases, leveraging its innovative platform to target triplet repeat disorders effectively. Triplet Therapeutics, Inc. was founded in 2019 and is headquartered in Cambridge, US.

The company is dedicated to pioneering treatments for triplet repeat disorders, utilizing advanced biotechnology. The founder, Nessan Bermingham, has a history of leadership in biotech ventures. In October 2022, Triplet Therapeutics, Inc. discontinued its operations after raising a total of USD 29.

39 mn in its latest funding round, a Series A led by investors including Alexandria Venture Investments and Pfizer Venture Investments. Triplet Therapeutics, Inc. focuses on developing innovative therapies specifically designed to address triplet repeat disorders, which are genetic conditions caused by the expansion of certain DNA sequences. The company's product offerings are centered on leveraging its proprietary platform to create effective treatment options for these challenging conditions.

Triplet Therapeutics, Inc. generates revenue primarily through strategic partnerships and funding rounds. The company’s recent funding in the Series A round was pivotal, contributing to its overall revenue of USD 29. 39 mn, which has been utilized for research and development of its therapeutic pipeline.

Following the recent funding round on October 12, 2022, Triplet Therapeutics, Inc. had anticipated launching new therapeutic candidates targeting triplet repeat disorders. However, as the company has since discontinued its operations, the future growth plans and market expansion strategies are no longer applicable.